These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25361817)

  • 21. Social anxiety disorder : current treatment recommendations.
    Muller JE; Koen L; Seedat S; Stein DJ
    CNS Drugs; 2005; 19(5):377-91. PubMed ID: 15907150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pregabalin: dose-response relationship in generalized anxiety disorder.
    Boschen MJ
    Pharmacopsychiatry; 2012 Mar; 45(2):51-6. PubMed ID: 22086745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy of social anxiety disorder: what does the evidence tell us?
    Davidson JR
    J Clin Psychiatry; 2006; 67 Suppl 12():20-6. PubMed ID: 17092192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model.
    Nutt D; Mandel F; Baldinetti F
    J Psychopharmacol; 2009 Nov; 23(8):867-73. PubMed ID: 18635690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment of childhood social anxiety disorder.
    Beidel DC; Ferrell C; Alfano CA; Yeganeh R
    Psychiatr Clin North Am; 2001 Dec; 24(4):831-46. PubMed ID: 11723636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.
    Kasper S; Brasser M; Schweizer E; Lyndon G; Prieto R
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):125-32. PubMed ID: 24290532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy for social anxiety disorder: a systematic review.
    Ipser JC; Kariuki CM; Stein DJ
    Expert Rev Neurother; 2008 Feb; 8(2):235-57. PubMed ID: 18271710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New approaches to the pharmacological management of generalized anxiety disorder.
    Buoli M; Caldiroli A; Caletti E; Paoli RA; Altamura AC
    Expert Opin Pharmacother; 2013 Feb; 14(2):175-84. PubMed ID: 23282069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview.
    Caldiroli A; Capuzzi E; Tagliabue I; Ledda L; Clerici M; Buoli M
    Expert Opin Pharmacother; 2023 Feb; 24(2):207-219. PubMed ID: 36519357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of pregabalin in alcohol dependence.
    Martinotti G; Di Nicola M; Tedeschi D; Mazza M; Janiri L; Bria P
    Adv Ther; 2008 Jun; 25(6):608-18. PubMed ID: 18553183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety.
    Vitali M; Tedeschini E; Mistretta M; Fehling K; Aceti F; Ceccanti M; Fava M
    J Clin Psychopharmacol; 2013 Feb; 33(1):95-8. PubMed ID: 23277244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregabalin: a new neuromodulator with broad therapeutic indications.
    Shneker BF; McAuley JW
    Ann Pharmacother; 2005 Dec; 39(12):2029-37. PubMed ID: 16288079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence-based treatment of anxiety disorders.
    Stein DJ
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 1():16-21. PubMed ID: 24931539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
    Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
    Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological treatment of social anxiety disorder.
    Masdrakis VG; Turic D; Baldwin DS
    Mod Trends Pharmacopsychiatry; 2013; 29():144-53. PubMed ID: 25225024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Issues and controversies surrounding the diagnosis and treatment of social anxiety disorder.
    Dalrymple KL
    Expert Rev Neurother; 2012 Aug; 12(8):993-1008; quiz 1009. PubMed ID: 23002942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.
    Feltner DE; Crockatt JG; Dubovsky SJ; Cohn CK; Shrivastava RK; Targum SD; Liu-Dumaw M; Carter CM; Pande AC
    J Clin Psychopharmacol; 2003 Jun; 23(3):240-9. PubMed ID: 12826986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pregabalin treatment of anxiety in patients with substance use disorders.
    Raza S; Siddiqui UA; Megna JL; Schwartz TL; Batki SL
    Ann Pharmacother; 2010 May; 44(5):937-8. PubMed ID: 20388860
    [No Abstract]   [Full Text] [Related]  

  • 39. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder.
    Boschen MJ
    Can J Psychiatry; 2011 Sep; 56(9):558-66. PubMed ID: 21959031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials.
    Bech P
    Pharmacopsychiatry; 2007 Jul; 40(4):163-8. PubMed ID: 17694480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.